Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of RGX-104 in combination of carboplatin/pemetrexed + pembrolizumab for the treatment of first-line treatment patients with non-small cell lung cancer (NSCLC)

Next Previous
Trial Profile

A phase 1/2 study of RGX-104 in combination of carboplatin/pemetrexed + pembrolizumab for the treatment of first-line treatment patients with non-small cell lung cancer (NSCLC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abequolixron (Primary) ; Carboplatin; Docetaxel; Pembrolizumab; Pemetrexed
  • Indications Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 07 Nov 2024 According to Florida Cancer Specialists & Research Institute media release, results from this study being presented this week at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston.
  • 30 Sep 2021 According to an Inspirna media release, Inspirna plans to provide an update from this study at its upcoming virtual R&D Day on Tuesday, October 26th, 2021 at 3:00 PM ET. The private event will be open to analysts and investors.; data from this clinical study is expected in 2H 2022.
  • 27 Apr 2020 According to an Rgenix media release, the company looks forward to sharing findings from this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top